Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 19OTHER 16NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Specimen Handling 18Cyclophosphamide 17Magnetic Resonance Spectroscopy 16Dexamethasone 15Cisplatin 14Vincristine 13Radiotherapy 13Radiation 11Etoposide 10Carboplatin 10durvalumab 9Radiotherapy, Intensity-Modulated 9Paclitaxel 9Doxorubicin 8Cytarabine 8Temozolomide 7Rituximab 7Prednisone 7Lenalidomide 7Irinotecan 7Gemcitabine 7Fluorouracil 7Docetaxel 7Bortezomib 7Biopsy 7daratumumab 6Platinum 6Leucovorin 6Capecitabine 6tremelimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × pomalidomide × Clear all
NCT04667663 2026-04-13

CPD-DARA

Cancer Trials Ireland

Phase 1 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

European Myeloma Network B.V.

Phase 3 Active not recruiting
117 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡